US stock · Healthcare sector · Medical Devices
Company Logo

Abiomed, Inc.

ABMDNASDAQ

262.50

USD
+8.22
(+3.23%)
Market Open
85.33P/E
46Forward P/E
3.29P/E to S&P500
11.961BMarket CAP
- -Div Yield
Upcoming Earnings
3 Aug-8 Aug
Shares Short
5/13/22
1.53M
Short % of Float
3.84%
Short % of Shares Outs.
3.36%
% Held by Insiders
1.99%
% Held by Institutions
94.57%
Beta
1.32
PEG Ratio
14.66
52w. high/low
379.30/226.46
Avg. Daily Volume
0.30M
Return %
Stock
S&P 500
1 year
(9.54)
(6.01)
3 years
(5.05)
39.24
5 years
85.13
63.25
Scale: |
High
Low
15.96
9.95
20.07
10.54
16.74
4.67
12.25
7.80
21.50
9.42
26.17
11.80
29.24
11.96
39.02
20.29
110.68
35.75
132.95
67.81
200.28
103.53
459.75
188.05
364.31
155.02
328.83
119.01
387.40
261.27
368.97
226.46
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Revenue per share
1.87
1.82
2.10
2.34
2.72
3.29
4.04
4.67
5.67
7.81
10.30
13.45
17.13
18.61
18.78
22.70
Earnings per share
(1.03)
(1.26)
(0.91)
(0.52)
(0.32)
0.04
0.38
0.19
2.80
0.90
1.21
2.54
5.77
4.49
5.00
3.00
FCF per share
(0.82)
(1.01)
(0.63)
(0.25)
(0.01)
0.05
0.60
0.53
0.94
1.45
1.50
3.10
4.64
6.00
4.90
5.49
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.09
0.12
0.11
0.05
0.05
0.05
0.07
0.07
0.13
0.37
1.17
1.27
0.98
0.97
1.18
0.79
Book Value per sh.
4.50
2.88
3.33
2.94
2.82
3.29
3.50
4.28
7.18
8.74
10.46
15.62
20.86
23.58
29.46
33.08
Comm.Shares outs.
27
32
35
37
37
38
39
39
41
42
43
44
45
45
45
45
Avg. annual P/E ratio
(12.4)
(12.2)
(9.4)
(19.2)
(46.7)
515.7
53.8
146.1
26.2
114.9
121.9
132.4
43.2
51.9
65.7
100.0
P/E to S&P500
(0.7)
(0.6)
(0.1)
(0.9)
(2.9)
34.7
3.2
8.0
1.3
5.2
5.2
5.3
1.8
1.4
2.2
3.9
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
51
59
73
86
101
126
158
184
230
330
445
594
769
841
848
1,032
Operating margin
(56.3)%
(61.9)%
(40.3)%
(29.3)%
(11.1)%
1.2%
10.5%
4.6%
12.4%
19.8%
20.2%
26.5%
29.2%
29.6%
27.1%
13.6%
Depreciation (m)
4
6
5
5
4
4
3
3
3
3
6
11
14
20
24
28
Net profit (m)
(28)
(41)
(32)
(19)
(12)
1
15
7
114
38
52
112
259
203
226
137
Income tax rate
(1.7)%
(1.3)%
(2.4)%
(3.7)%
(8.2)%
41.2%
11.0%
13.8%
(295.2)%
42.1%
42.9%
30.1%
1.6%
21.0%
21.8%
28.4%
Net profit margin
(55.0)%
(69.4)%
(43.2)%
(22.2)%
(11.6)%
1.2%
9.5%
4.0%
49.4%
11.6%
11.7%
18.9%
33.7%
24.1%
26.6%
13.2%
Working capital (m)
83
52
71
65
62
88
90
88
181
242
257
410
571
504
659
838
Long-term debt (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Equity (m)
122
94
116
108
105
126
137
168
292
369
452
690
937
1,065
1,330
1,503
ROIC
(22.6)%
(41.5)%
(26.7)%
(17.1)%
(10.8)%
1.1%
10.5%
4.2%
38.0%
10.1%
10.8%
16.0%
27.3%
18.7%
16.5%
8.9%
Return on capital
(20.1)%
(34.2)%
(22.7)%
(14.2)%
(8.3)%
1.7%
9.9%
4.2%
8.5%
15.5%
16.6%
20.4%
25.0%
21.1%
19.3%
11.4%
Return on equity
(22.8)%
(43.7)%
(27.2)%
(17.6)%
(11.2)%
1.2%
11.0%
4.4%
39.0%
10.3%
11.5%
16.3%
27.6%
19.1%
17.0%
9.1%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
(22.4)%
64.9%
2.1%
- -
- -
- -
- -
- -
31.3%
5.1%
- -
Capital Structure
20 May · 2022 | Q4
All numbers in millions
Total liabilities
$ 170
Total assets
$ 1,673
Long-term debt
$ - -
Cash and equiv.
$ 133
Goodwill
$ 77
Retained earnings
$ 965
Common stock
46
Enterprise Value
$ 11,828
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
443
584
759
Receivables
85
97
91
Inventory
90
81
94
Other
18
66
(26)
Current assets
636
788
976
Acc. Payable
33
35
35
Debt due
- -
- -
- -
Other
99
94
103
Current liabilities
132
129
138
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
21.74%
15.35%
23.83%
Cash flow
12.85%
19.24%
36.27%
Earnings
(39.47)%
20.23%
173.54%
Dividends
- -
- -
- -
Book value
13.06%
21.86%
31.67%
Insider Trading
Type
Shares
Date
Sutter Martin P
Sale
15
05/18/22
Sutter Martin P
Sale
103
05/18/22
Sutter Martin P
Sale
155
05/18/22
Sutter Martin P
Sale
167
05/18/22
Sutter Martin P
Sale
22
05/18/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
208
205
222
207
841
2021
165
210
232
241
848
2022
253
248
261
270
1,032
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
1.97
0.29
1.53
0.70
4.49
2021
0.99
1.38
1.37
1.26
5.00
2022
(0.58)
1.25
1.01
1.33
3.00
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Devices
CEO:
Mr. Michael Minogue
Full-time employees:
1,725
City:
Danvers
Address:
22 CHERRY HILL DR
IPO:
Jul 29, 1987
Website:
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.